ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,241 to 2,260 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Influenza Vaccine vs Placebo: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens35 of 1,792

62 of 1,817

-1.5 points

-2.5 to -0.4

3,609NCT00566345

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

Intervention vs Control: Prevalence of Chronic Kidney Disease (CKD)361 of 2,100

248 of 1,505

0.7 points

-1.8 to 3.2

3,605NCT01864603

Sustainable East Africa Research in Community Health

Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Non-Coronary Artery Bypass Grafting-Related Major Bleeding89 of 1,800

149 of 1,802

-3.3 points

-5.0 to -1.7

3,602NCT00433966

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Cardiovascular Events379 of 1,800

377 of 1,802

0.1 points

-2.5 to 2.8

3,602NCT00433966

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Cardiovascular Events98 of 1,800

99 of 1,802

-0.0 points

-1.5 to 1.4

3,602NCT00433966

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

Pharmacology Arm - Bivalirudin vs Pharmacology Arm - Unfractionated Heparin: Pharmacology Arm - Major Adverse Ischemic Cardiac Events and Major Bleeding Events166 of 1,800

218 of 1,802

-2.9 points

-4.9 to -0.9

3,602NCT00433966

Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction

RSV Season 1: Clesrovimab 105 mg vs RSV Season 1: Placebo: RSV Season 1: Number of Participants With RSV-Associated MALRI64 of 2,398

77 of 1,201

-3.7 points

-5.4 to -2.3

3,599NCT04767373

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

RSV Season 1: Clesrovimab 105 mg vs RSV Season 1: Placebo: RSV Season 1: Number of Participants With Respiratory Syncytial Virus (RSV)-Associated Medically Attended Lower Respiratory Infection (MALRI)60 of 2,398

74 of 1,201

-3.7 points

-5.3 to -2.2

3,599NCT04767373

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

RSV Season 1: Clesrovimab 105 mg vs RSV Season 1: Placebo: RSV Season 1: Number of Participants With RSV-Associated Hospitalization9 of 2,398

28 of 1,201

-2.0 points

-3.0 to -1.2

3,599NCT04767373

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: All Cause Mortality at 30 Days18 of 2,708

3 of 885

0.3 points

-0.4 to 0.8

3,593NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: 30-day Composite Major Adverse Cardiac Event (MACE)256 of 2,706

83 of 886

0.1 points

-2.3 to 2.2

3,592NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

Aclidinium Bromide vs Placebo: Number of Participants With Major Adverse Cardiovascular Event (MACE) - on Study Analysis69 of 1,791

76 of 1,798

-0.4 points

-1.7 to 0.9

3,589NCT01966107

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

Aclidinium Bromide vs Placebo: Number of Participants With Major Adverse Cardiovascular Event (MACE) or Other Serious Cardiovascular Events of Interest - On-study Analysis168 of 1,791

160 of 1,798

0.5 points

-1.4 to 2.4

3,589NCT01966107

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

Aclidinium Bromide vs Placebo: deaths from any cause75 of 1,791

64 of 1,798

0.6 points

-0.6 to 1.9

3,589NCT01966107

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

Aclidinium Bromide vs Placebo: serious adverse events409 of 1,791

356 of 1,798

3.0 points

0.4 to 5.7

3,589NCT01966107

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Rate of Stent Thrombosis16 of 2,695

7 of 883

-0.2 points

-1.1 to 0.4

3,578NCT01116882

Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings

M72AS01 Group vs Control Group: Number of Subjects With Serious Adverse Events (SAEs).51 of 1,786

62 of 1,787

-0.6 points

-1.8 to 0.5

3,573NCT01755598

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

M72AS01 Group vs Control Group: Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)2 of 1,786

6 of 1,787

-0.2 points

-0.6 to 0.1

3,573NCT01755598

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

M72AS01 Group vs Control Group: Number of Subjects With Any Unsolicited Adverse Events (AEs).1,207 of 1,786

816 of 1,787

21.9 points

18.7 to 25.1

3,573NCT01755598

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

M72AS01 Group vs Control Group: deaths from any cause19 of 1,786

28 of 1,787

-0.5 points

-1.3 to 0.3

3,573NCT01755598

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=113"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=113

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00566345-07e0ff93",
        "title": "Influenza Vaccine vs Placebo: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens",
        "summary": "35 of 1792 against 62 of 1817; risk difference -1.5 points, 95% interval -2.5 to -0.4; NCT00566345, Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)",
        "record": "/library/comparisons/NCT00566345-07e0ff93",
        "nct_id": "NCT00566345",
        "kind": "outcome",
        "participants": 3609,
        "risk_difference": {
          "value": -0.014590929416620803,
          "lower": -0.02544081129984007,
          "upper": -0.004038257515273909
        },
        "group_1": "35 of 1,792",
        "group_2": "62 of 1,817",
        "difference": "-1.5 points",
        "interval": "-2.5 to -0.4",
        "trial_title": "Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)"
      },
      {
        "id": "NCT01864603-1a6b1362",
        "title": "Intervention vs Control: Prevalence of Chronic Kidney Disease (CKD)",
        "summary": "361 of 2100 against 248 of 1505; risk difference 0.7 points, 95% interval -1.8 to 3.2; NCT01864603, Sustainable East Africa Research in Community Health",
        "record": "/library/comparisons/NCT01864603-1a6b1362",
        "nct_id": "NCT01864603",
        "kind": "outcome",
        "participants": 3605,
        "risk_difference": {
          "value": 0.007120708748615701,
          "lower": -0.017882447636257383,
          "upper": 0.03161252654836551
        },
        "group_1": "361 of 2,100",
        "group_2": "248 of 1,505",
        "difference": "0.7 points",
        "interval": "-1.8 to 3.2",
        "trial_title": "Sustainable East Africa Research in Community Health"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=114",
  "request_id": "l_QTALtvclvv_r7I"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?